Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

K Clément; Erica Akker; J Argente; A Bahm; Kuan Chung; H Connors

doi:10.1016/s2213-8587(20)30364-8

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

K Clément, Erica Akker, J Argente, A Bahm, Kuan Chung, H Connors

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

334 Citations (Scopus)

Original language	English
Pages (from-to)	960-970
Number of pages	11
Journal	The Lancet Diabetes and Endocrinology
Volume	8
Issue number	12
DOIs	https://doi.org/10.1016/s2213-8587(20)30364-8
Publication status	Published - 2020

Research programs

EMC MM-01-54-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s2213-8587(20)30364-8

http://hdl.handle.net/1765/133544

Cite this

@article{27f04027e3d84b65a4be55f8fdd0ed3b,

title = "Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials",

author = "K Cl{\'e}ment and Erica Akker and J Argente and A Bahm and Kuan Chung and H Connors",

year = "2020",

doi = "10.1016/s2213-8587(20)30364-8",

language = "English",

volume = "8",

pages = "960--970",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "UniCeSV - Universita degli Studi di Firenze",

number = "12",

}

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. / Clément, K; Akker, Erica; Argente, J et al.
In: The Lancet Diabetes and Endocrinology, Vol. 8, No. 12, 2020, p. 960-970.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

AU - Clément, K

AU - Akker, Erica

AU - Argente, J

AU - Bahm, A

AU - Chung, Kuan

AU - Connors, H

PY - 2020

Y1 - 2020

U2 - 10.1016/s2213-8587(20)30364-8

DO - 10.1016/s2213-8587(20)30364-8

M3 - Article

SN - 2213-8587

VL - 8

SP - 960

EP - 970

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 12

ER -